User profiles for Laura L. Hammitt
 | Laura HammittJohns Hopkins Bloomberg School of Public Health Verified email at jhu.edu Cited by 5533 |
[HTML][HTML] Nirsevimab for prevention of RSV in healthy late-preterm and term infants
LL Hammitt, R Dagan, Y Yuan… - … England Journal of …, 2022 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion …
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion …
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
…, D Cooper, RW Frenck Jr, LL Hammitt… - New England journal …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
…, D Cooper, RW Frenck Jr, LL Hammitt… - … England Journal of …, 2021 - Mass Medical Soc
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
[HTML][HTML] Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine
…, M Berhe, D Fitz-Patrick, LL Hammitt… - New England journal …, 2022 - Mass Medical Soc
Background Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a
critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
Nirsevimab for prevention of RSV in term and late-preterm infants
…, M Bosheva, R Dagan, LL Hammitt… - … England Journal of …, 2023 - Mass Medical Soc
Nirsevimab to Prevent RSV Illness in Infants Nirsevimab, a monoclonal antibody targeting
respiratory syncytial virus, protected against RSV-associated hospitalization and severe …
respiratory syncytial virus, protected against RSV-associated hospitalization and severe …
Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine …
RJ Singleton, TW Hennessy, LR Bulkow, LL Hammitt… - Jama, 2007 - jamanetwork.com
ContextWith routine childhood vaccination using heptavalent pneumococcal conjugate
vaccine, one concern has been the potential for emergence and expansion of replacement …
vaccine, one concern has been the potential for emergence and expansion of replacement …
[HTML][HTML] Early outpatient treatment for Covid-19 with convalescent plasma
…, D Cruser, K Oei, M Abinante, LL Hammitt… - … England Journal of …, 2022 - Mass Medical Soc
Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing …
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing …
Indirect Effect of Conjugate Vaccine on Adult Carriage of Streptococcus pneumoniae: An Explanation of Trends in Invasive Pneumococcal Disease
LL Hammitt, DL Bruden, JC Butler… - The Journal of …, 2006 - academic.oup.com
BackgroundUse of heptavalent protein-polysaccharide pneumococcal conjugate vaccine (PCV7)
has been associated with decreases in PCV7-type invasive pneumococcal disease …
has been associated with decreases in PCV7-type invasive pneumococcal disease …
[HTML][HTML] Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study
…, HC Baggett, WA Brooks, DR Feikin, LL Hammitt… - The Lancet, 2019 - thelancet.com
Background Pneumonia is the leading cause of death among children younger than 5 years.
In this study, we estimated causes of pneumonia in young African and Asian children, using …
In this study, we estimated causes of pneumonia in young African and Asian children, using …
[HTML][HTML] Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus …
LL Hammitt, DO Akech, SC Morpeth, A Karani… - The Lancet Global …, 2014 - thelancet.com
Background The effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed
countries was enhanced by indirect protection of unvaccinated individuals, mediated by …
countries was enhanced by indirect protection of unvaccinated individuals, mediated by …
